←Back to Expert Scholars
Translational Medicine / 转化医学Checkpoint Combinations, Novel Immunotherapy
Omid Hamid
MD
🏢The Angeles Clinic and Research Institute🌐USA
Chief, Translational Research and Immuno-Oncology
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Omid Hamid leads translational immuno-oncology at The Angeles Clinic and has conducted numerous first-in-human trials of checkpoint combinations including TIGIT agents and novel IO targets. He has advanced TIL therapy in melanoma. His work explores next-generation immunotherapy combinations.
Share:
🧪Research Fields 研究领域
early phase immunotherapy
TIGIT combinations
TIL therapy
melanoma
checkpoint combinations
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Omid Hamid 的研究动态
Follow Omid Hamid's research updates
留下邮箱，当我们发布与 Omid Hamid（The Angeles Clinic and Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment